COVID-19 vaccines have saved millions of lives; however, understanding the long-term effectiveness of these vaccines is imperative to developing recommendations for booster doses and other precautions. Comparisons of mortality rates between more and less vaccinated groups may be misleading due to selection bias, as these groups may differ in underlying health status. We studied all adult deaths during the period of 1 April 2021–30 June 2022 in Milwaukee County, Wisconsin, linked to vaccination records, and we used mortality from other natural causes to proxy for underlying health. We report relative COVID-19 mortality risk (RMR) for those vaccinated with two and three doses versus the unvaccinated, using a novel outcome measure that controls for selection effects. This measure, COVID Excess Mortality Percentage (CEMP), uses the non-COVID natural mortality rate (Non-COVID-NMR) as a measure of population risk of COVID mortality without vaccination. We validate this measure during the pre-vaccine period (Pearson correlation coefficient = 0.97) and demonstrate that selection effects are large, with non-COVID-NMRs for two-dose vaccinees often less than half those for the unvaccinated, and non-COVID NMRs often still lower for three-dose (booster) recipients. Progressive waning of two-dose effectiveness is observed, with an RMR of 10.6% for two-dose vaccinees aged 60+ versus the unvaccinated during April–June 2021, rising steadily to 36.2% during the Omicron period (January–June, 2022). A booster dose reduced RMR to 9.5% and 10.8% for ages 60+ during the two periods when boosters were available (October–December, 2021; January–June, 2022). Boosters thus provide important additional protection against mortality.
Prior research generally finds that the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA1273) COVID-19 vaccines provide similar protection against mortality, sometimes with a Moderna advantage due to slower waning. However, most comparisons do not address selection effects for those who are vaccinated and with which vaccine. We report evidence on large selection effects, and use a novel method to control for these effects. Instead of directly studying COVID-19 mortality, we study the COVID-19 excess mortality percentage (CEMP), defined as the COVID-19 deaths divided by non-COVID-19 natural deaths for the same population, converted to a percentage. The CEMP measure uses non-COVID-19 natural deaths to proxy for population health and control for selection effects. We report the relative mortality risk (RMR) for each vaccine relative to the unvaccinated population and to the other vaccine, using linked mortality and vaccination records for all adults in Milwaukee County, Wisconsin, from 1 April 2021 through 30 June 2022. For two-dose vaccinees aged 60+, RMRs for Pfizer vaccinees were consistently over twice those for Moderna, and averaged 248% of Moderna (95% CI = 175%,353%). In the Omicron period, Pfizer RMR was 57% versus 23% for Moderna. Both vaccines demonstrated waning of two-dose effectiveness over time, especially for ages 60+. For booster recipients, the Pfizer–Moderna gap is much smaller and statistically insignificant. A possible explanation for the Moderna advantage for older persons is the higher Moderna dose of 100 μg, versus 30 μg for Pfizer. Younger persons (aged 18–59) were well-protected against death by two doses of either vaccine, and highly protected by three doses (no deaths among over 100,000 vaccinees). These results support the importance of a booster dose for ages 60+, especially for Pfizer recipients. They suggest, but do not prove, that a larger vaccine dose may be appropriate for older persons than for younger persons.
14 October 2021 in Journal of Environmental Economics and Management
This paper studies the effect of the economic impact payment (EIP) on individual contributions to COVID-19 mitigation efforts in the USA, where the mitigation efforts are measured by the reduction of daily human mobility. I empirically estimate the effect of the EIP in April 2020 and use cellphone GPS data of 45 million smartphone devices as a proxy for human mobility across 216,069 Census Block Groups. The results show that when receiving the EIP, households significantly increased “Median Home Dwell Time” by an average of 3–5% (about 26–45 min). The paper highlights this unintended effect of the EIP, namely, that in addition to providing economic assistance, the EIP also helped increase individual contributions to mitigation efforts that slowed COVID-19 virus transmission in early 2020.
The Pfizer and Moderna COVID-19 vaccines have often been described as providing similar protection against mortality. However, most comparisons do not take into account the potential selection effects for who gets vaccinated, with how many doses, when, and with which vaccine. We report evidence on large selection effects and use a novel method to control for these effects. Instead of studying COVID-19 mortality, we study the COVID-19 Excess Mortality Percentage (CEMP), defined as COVID-19 deaths divided by non-COVID natural deaths for the same population. The CEMP measure uses non-COVID-19 natural deaths as a proxy for population health and thus controls, albeit imperfectly, for selection effects. We study adults vaccinated with the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA1273) vaccines, and report mortality risk (RMR) for each vaccine relative to the unvaccinated and to the other vaccine, using linked mortality and vaccination records for Milwaukee County, Wisconsin, through June 30, 2022. The vaccines provided similar protection for persons aged 18-59, but for persons aged 60+, RMRs for two-dose Pfizer vaccinees were over twice those for Moderna vaccinees. Pfizer two-dose RMR for ages 60+ over April 2021-June 2022 was 248% of Moderna [95% CI=175%,353%]; in the Omicron period, Pfizer RMR was 57% versus 23% for Moderna. Both vaccines demonstrated waning two-dose effectiveness over time, especially for ages 60+. For booster recipients, the Pfizer-Moderna gap narrowed and became statistically insignificant. Younger persons (aged 18-59) were well-protected against death by two doses of either vaccine and highly protected by three doses (no deaths in our sample among over 100,000 vaccinees). These results support booster importance for ages 60+, especially for Pfizer recipients. The Online Appendix for this paper is available at http://ssrn.com/abstract=4321773
We estimate the impact of province-specific pollution reduction targets on firms’ markups in the Chinese manufacturing sector. China’s Eleventh Five-Year Plan mandated $$\hbox {SO}_2$$ reduction targets that varied across provinces, providing a natural experiment to analyze the effects of environmental regulation stringency on firms’ performance. Using a detailed firm-level dataset covering 85–90% of China’s industrial value-added between 1998 and 2007, we find that more stringent environmental regulations caused a 1.54% decrease in firms’ markups. High-pollution industries, non-exporters, and state-owned firms were particularly sensitive to the regulation stringency. To investigate the underlying mechanisms, we analyze firm-level output and $$\hbox {SO}_2$$ emissions and find evidence that firms reduced production and emissions in response to tighter regulation, consistent with a supply-side adjustment. While existing literature predominantly focuses on the relationship between environmental regulations and firms’ productivity, we emphasize the importance of markup effects for a more comprehensive understanding of the overall impacts of environmental regulations on firm performance and market dynamics.